The Poliomyelitis drugs in development market research report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Poliomyelitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued products.

GlobalData tracks 38 drugs in development for Poliomyelitis by 32 companies/universities/institutes. The top development phase for Poliomyelitis is phase iii with 11 drugs in that stage. The Poliomyelitis pipeline has 26 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Poliomyelitis pipeline products market are: Indian Immunologicals, University of Antwerp and Serum Institute of India.

The key targets in the Poliomyelitis pipeline products market include Diphtheria Toxin, Pertussis Toxin, and Tetanus Toxin.

The key mechanisms of action in the Poliomyelitis pipeline product include Toll Like Receptor 5 (Toll/Interleukin 1 Receptor Like Protein 3 or TLR5) Agonist with one drug in Preclinical. The Poliomyelitis pipeline products include six routes of administration with the top ROA being Intramuscular and eight key molecule types in the Poliomyelitis pipeline products market including Inactivated Vaccine, and Toxoid Vaccine.

Poliomyelitis overview

Polio is a highly infectious disease caused by a virus. It invades the nervous system and can cause total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck, and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

For a complete picture of Poliomyelitis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.